Lung Cancer Multiple Reaction Monitoring Project

背景：基因组数据集通过识别人类癌症中的靶向突变，引发了精确肿瘤学的革命。 这导致了基于下一代DNA测序的诊断面板的产生，这些面板现在已被整合到试验中。 不幸的是，在试图可靠地预测哪些患者的肿瘤对任何给定的治疗有反应时，仍然存在关键的生物学缺失。 CPTAC将开发多反应监测（MRM）和/或免疫MRM检测的社区资源，这些检测将检测和定量肺癌组的人类蛋白质，以补充目前临床上使用的靶向基因组，并根据需要提供其他组。

Background: Genomic Datasets have spurred a revolution in precision oncology by identifying targetable mutations in human cancers. This has led to the generation of Next-gen DNA sequencing-based diagnostic panels that are now integrated into trials. Unfortunately, there is still key missing biology when trying to reliably predict which patient's tumors respond to any given therapy. CPTAC will develop a community resource of multiple reaction monitoring (MRM) and/or Immuno-MRM assays that will detect and quantitate human proteins for lung cancer panels to complement targeted genomic panels currently used in the clinic, and other panels as needed.